Frontier mental health research: psychedelics & drug studies
Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.
Health Claims About Cannabidiol Products: A Retrospective Analysis of U.S. Food and Drug Administration Warning Letters from 2015 to 2019
The study examined 39 FDA Warning Letters about CBD products issued from 2015 to 2019. It found most violations were online (websites and social media) and that nearly all letters (97%) cited companies marketing CBD as an unapproved drug. The letters also showed widespread claims that CBD could treat many…
Comparative Pharmacokinetics of Commercially Available Cannabidiol Isolate, Broad-Spectrum, and Full-Spectrum Products
This study gave the same oral dose of cannabidiol (CBD) to male and female rats using three product types: isolate, broad‑spectrum, and full‑spectrum. When CBD was given as a full‑spectrum product that included about 0.2% THC, CBD blood levels were higher than with isolate or broad‑spectrum. Lab tests showed THC…
